Tuesday, March 11, 2025 5:17:47 PM
We have differing understandings of the situation. FDA wants to see commercial production capability that it can inspect. We agree on that.
Where we have differing views is I don't think the FDA is concerned with capacity, you do.
It appears to me that the company understands its lack of capacity to service the US market if it were to be approved before EDEN as an approved production source so it has decided not to pursue the FDA BLA until it is in a position to service the expected demand. I think that decision is a function of the lack of money available so the company is not spending on things that will not provide a rapid return.
I hope that the company starts the FDA BLA process as soon as the UK approves with the expectation that EDEN will be approved by the time the FDA acts. Of course the company knows how far along the EDEN development is and when they expect it to be approved. Based on that knowledge they will apply to the FDA at the appropriate time.
Where we have differing views is I don't think the FDA is concerned with capacity, you do.
It appears to me that the company understands its lack of capacity to service the US market if it were to be approved before EDEN as an approved production source so it has decided not to pursue the FDA BLA until it is in a position to service the expected demand. I think that decision is a function of the lack of money available so the company is not spending on things that will not provide a rapid return.
I hope that the company starts the FDA BLA process as soon as the UK approves with the expectation that EDEN will be approved by the time the FDA acts. Of course the company knows how far along the EDEN development is and when they expect it to be approved. Based on that knowledge they will apply to the FDA at the appropriate time.
Nunc est Bibendum
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
